BM 573

Known as: BM-573, BM573 cpd 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2016
012320012016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Endothelial dysfunction is considered to be an early event in atherosclerosis and plays a pivotal role in the development… (More)
Is this relevant?
2011
2011
Atherosclerosis is the principal cause of mortality in industrialized countries. Its development is influenced by several… (More)
  • table 1
  • figure 2
  • figure 5
Is this relevant?
2007
2007
Atherosclerosis is a chronic inflammatory disease of the vasculature influenced by a variety of mediators. Among them… (More)
Is this relevant?
2006
2006
AIMS To investigate whether BM-573 (N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea), an original combined… (More)
Is this relevant?
2004
2004
The aim of this study was to evaluate the effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea… (More)
Is this relevant?
2004
2004
The aim of this study was to evaluate the effect of BM-573, a dual thromboxane A2 synthase inhibitor and receptor antagonist, on… (More)
Is this relevant?
2003
2003
The aim of this study was to characterize the effects of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2003
2003
We studied the effects on pulmonary hemodynamics of U-46619, a thromboxane A2 (TXA2) agonist, before and after administration of… (More)
Is this relevant?
2003
2003
Thromboxane A2 is considered to be partially responsible for the increase in pulmonary vascular resistance observed after… (More)
Is this relevant?
2001
2001
The pharmacomodulation of sulfonylureas structurally related to torasemide and characterized by a TXA(2)antagonism led to the… (More)
Is this relevant?